Related references
Note: Only part of the references are listed.The lncRNAs LINC00261 and LINC00665 are upregulated in long-term prostate cancer adaptation after radiotherapy
Iris Eke et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2021)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy
Iris Eke et al.
NUCLEIC ACIDS RESEARCH (2020)
Circumventing AKT-Associated Radioresistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capivasertib
Liwei Lang et al.
CELLS (2020)
Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells
Asmita Sharda et al.
CLINICAL EPIGENETICS (2020)
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K. S. Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib
Wenxiao Jia et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Claire L. Vale et al.
LANCET (2020)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Iris Eke et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer
Iris Eke et al.
MOLECULAR CANCER RESEARCH (2018)
Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis
Li Sun et al.
CELL DEATH & DISEASE (2018)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence
Yngve Nordby et al.
SCIENTIFIC REPORTS (2017)
IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer
Tamara Aleksic et al.
BRITISH JOURNAL OF CANCER (2017)
Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine
Iris Eke et al.
CANCER LETTERS (2016)
Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report
G. Janoray et al.
CANCER RADIOTHERAPIE (2016)
An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Claudia Peitzsch et al.
CANCER RESEARCH (2016)
Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
Malte Kriegs et al.
ONCOTARGET (2016)
IGF-1R inhibition sensitizes breast cancer cells to ATM-Related Kinase (ATR) inhibitor and cisplatin
Ciara H. O'Flanagan et al.
ONCOTARGET (2016)
Radiation oncology in the era of precision medicine
Michael Baumann et al.
NATURE REVIEWS CANCER (2016)
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Matthew K. H. Hong et al.
NATURE COMMUNICATIONS (2015)
PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
L. Chang et al.
CELL DEATH & DISEASE (2014)
EGFR/JIP-4/JNK2 Signaling Attenuates Cetuximab-Mediated Radiosensitization of Squamous Cell Carcinoma Cells
Iris Eke et al.
CANCER RESEARCH (2013)
Cetuximab Attenuates Its Cytotoxic and Radiosensitizing Potential by Inducing Fibronectin Biosynthesis
Iris Eke et al.
CANCER RESEARCH (2013)
Radiation Survivors: Understanding and Exploiting the Phenotype following Fractionated Radiation Therapy
Adeola Y. Makinde et al.
MOLECULAR CANCER RESEARCH (2013)
Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
K. Ted Thurn et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Re-irradiation for salvage of prostate cancer failures after primary radiotherapy
Stephen J. Ramey et al.
WORLD JOURNAL OF UROLOGY (2013)
ROBOTIC IMAGE-GUIDED STEREOTACTIC RADIOTHERAPY, FOR ISOLATED RECURRENT PRIMARY, LYMPH NODE OR METASTATIC PROSTATE CANCER
Barbara Alicja Jereczek-Fossa et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Niranjan Awasthi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy
Beate C. Litzenburger et al.
CLINICAL CANCER RESEARCH (2011)
A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).
K. K. Ang et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures
Iris Eke et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Three-Dimensional Cell Growth Confers Radioresistance by Chromatin Density Modification
Katja Storch et al.
CANCER RESEARCH (2010)
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1α
Iris Eke et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2009)
Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors
Mechthild Krause et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2009)
Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831
Michele Y. Halyard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Postradiation sensitization of the histone deacetylase inhibitor valproic acid
Prakash Chinnaiyan et al.
CLINICAL CANCER RESEARCH (2008)
Inhibition of histone deacetylation: A strategy for tumor radiosensitization
Kevin Camphausen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Radiation-induced EGFR-signaling and control of DNA-damage repair
H. Peter Rodemann et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2007)
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer
JI Kreisberg et al.
CANCER RESEARCH (2004)
Comparison of in vitro and in vivo α/β ratios for prostate cancer
DJ Carlson et al.
PHYSICS IN MEDICINE AND BIOLOGY (2004)
Share Paper
